The Boardroom Series: Interview with Orphazyme's CMO Carlos Camozzi Full Interview




Dr Carlos Camozzi is the new Chief Medical Officer at the Biotech Company Orphazyme, located in Denmark. Carlos has over 25 years in clinical research and development roles in pharma and biotech companies, including leading clinical operations in the rare disease area. Before joining Orphazyme, Dr Camozzi was the VP CMO of uniQure (ex AMT) in Netherlands, and prior to that, he was Medical Director and Head of Medical Affairs with Orphan Europe.

 The landscape for the Pharma industry has changed, both from a scientific and regulatory standpoint. Business models must change in order to stay relevant and deliver the best results for patients. In this Interview Carlos Camozzi argues that a future based on finding the next blockbuster will be difficult and that real advances can be made by shifting focus onto diagnostics and treatments for rare diseases.

TO READ THE FULL STORY